Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 251 to 300 of 761

TitleReference numberPublishedLast updated
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA733
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)TA731
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Midostaurin for treating advanced systemic mastocytosisTA728
Sapropterin for treating hyperphenylalaninaemia in phenylketonuriaTA729
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA722
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndromeTA139
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphomaTA720
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancerTA721
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating axial spondyloarthritisTA718
Secukinumab for treating non-radiographic axial spondyloarthritisTA719
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillationTA249
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillationTA256
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA355
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitisTA708
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Ravulizumab for treating atypical haemolytic uraemic syndromeTA710
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA696
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Avelumab for treating metastatic Merkel cell carcinomaTA517
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Selective internal radiation therapies for treating hepatocellular carcinomaTA688

Results per page

  1. 10
  2. 25
  3. 50
  4. All